IP Library Granted Patent US 7,868,191
Granted Patent B2
US 7,868,191 · App. 12/310,216 · Granted Jan 11, 2011

Preparation and purification of mupirocin calcium

Assignee: Xellia Pharmaceuticals ApS
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,868,191
App. No.
12/310,216
Granted
Jan 11, 2011
Kind
B2
Abstract

The present invention relates to methods for the preparation and purification of mupirocin calcium. The process comprises adsorbing mupirocin to a hydrophobic adsorbent resin, exposing the bound mupirocin to a calcium-containing solution, washing impurities from the resin and eluting purified mupirocin calcium from the resin.

Claims (19)

1. A method for purifying mupirocin calcium comprising adsorbing a preparation of mupirocin to a hydrophobic solid support to produce bound mupirocin, exposing the bound mupirocin to a soluble calcium-containing agent to produce mupirocin calcium, washing the bound mupirocin calcium, and eluting purified mupirocin calcium from the solid support.

2. The method of claim 1 wherein the preparation of mupirocin is prepared by fermenting a mupirocin-producing culture of Pseudomonas fluorescens , obtaining the fermentation broth produced thereby, and optionally clarifying the broth by filtration.

3. The method of claim 1 wherein the solid support is a hydrophobic adsorbent resin.

4. The method of claim 3 wherein the resin comprises modified silica, a polystyrene or an acrylic material.

5. The method of claim 4 wherein the resin comprises acrylic adsorbent XAD7HP, or the polystyrene divinylbenzene adsorbents XAD1600 or XAD4.

6. The method of claim 1 wherein the mupirocin calcium is further purified by crystallization.

7. The method of claim 1 wherein the mupirocin calcium is purified to at least 50%.

8. The method of claim 1 wherein the mupirocin calcium is purified to at least 65%.

9. The method of claim 1 wherein the mupirocin calcium is purified to at least 90%.

10. The method of claim 1 wherein a base is added to the preparation of mupirocin to aid adsorption to the solid support.

11. The method of claim 1 wherein the calcium-containing agent comprises calcium acetate, calcium chloride, calcium nitrate or calcium propionate.

12. The method of claim 1 wherein the preparation of mupirocin is in the form of pseudomonate, ammonium sulfate solution is added to the preparation of mupirocin to aid adsorption of the mupirocin to the solid support, the solid support is the acrylic adsorbent XAD7HP or the polystyrene divinylbenzene adsorbent XAD 1600, the calcium containing agent is calcium acetate, and the purified mupirocin calcium is eluted using an organic solvent.

13. The method of claim 1 wherein the preparation of mupirocin is in the form of mupirocin acid, ammonium sulfate solution is added to the preparation of mupirocin to aid adsorption of the mupirocin to the solid support, the solid support is the polystyrene divinylbenzene adsorbent XAD4, the calcium-containing agent is calcium chloride and the purified mupirocin calcium is eluted using an organic solvent.

14. The method of claim 11 wherein the calcium-containing solution comprises calcium acetate.

15. The method of claim 11 wherein the calcium-containing solution comprises calcium chloride.

16. The method of claim 1 wherein mupirocin calcium is eluted from the solid support using an organic solvent.

17. The method of claim 16 wherein the organic solvent comprises methanol.

18. The method of claim 1 wherein the mupirocin is in the form of pseudomonate, ammonium sulfate solution is added to the mupirocin to aid adsorption of the mupirocin to the solid support, the solid support is the acrylic adsorbent XAD7HP or the polystyrene divinylbenzene adsorbent XAD 1600 and the mupirocin calcium is eluted using an organic solvent.

19. The method of claim 1 wherein the mupirocin is in the form of mupirocin acid, ammonium sulfate solution is added to the mupirocin to aid adsorption of the mupirocin to the solid support, the solid support is the polystyrene divinylbenzene adsorbent XAD4, the calcium-containing solution is calcium chloride and the mupirocin calcium is eluted using an organic solvent.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2012
From: XELLIA PHARMACEUTICALS APS
To: SYNGEN BIOTECH CO., LTD.
Reel/Frame 029238/0339 →
CHANGE OF NAME Recorded Sep 30, 2010
From: AXELLIA PHARMACEUTICALS APS
To: XELLIA PHARMACEUTICALS APS
Reel/Frame 025075/0292 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2009
From: AASSVEEN, LENE
To: AXELLIA PHARMACEUTICALS APS
Reel/Frame 023121/0746 →
Priority Claims (1)
GB 0617069.0 · Aug 30, 2006 · national
Continuity (1)
Related Publication 20090240071A1 · Sep 24, 2009